Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company is headquartered in Palo Alto, CA.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA.

Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome and evolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet. Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn. Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T cells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.

LanzaTech is turning our global carbon crisis into a feedstock opportunity with the potential to displace 30% of crude oil use today and reduce global CO2 emissions by 10%. By recycling carbon from industrial off-gases; syngas generated from any biomass resource (e.g. municipal solid waste (MSW), organic industrial waste, agricultural waste); and reformed biogas, LanzaTech can reduce emissions and make new products for a circular carbon economy. LanzaTech’s carbon recycling technology is like retrofitting a brewery onto an emission source like a steel mill or a landfill site, but instead of using sugars and yeast to make beer, pollution is converted by bacteria to fuels and chemicals! Imagine a day when your plane is powered by recycled GHG emissions, when your yoga pants started life as pollution from a steel mill. This future is possible using LanzaTech technology.

Guangdong Tiankeya Biomedical Technology Co., Ltd., established on 2019-01-10, Business scope includes research and development of biological products(Does not include licensed operations);Medical technology research and development;Health Sciences Program Research,to develop;Human Science Research,to develop;Natural science research and experimental development;Stem Cell Technology Research,to develop;Biomedical Technology Research;Pharmaceutical Research Services;Stem Cell Drug Development;Medical Research and Experimental Development;Operation of non-licensed medical devices;Research and development of biodiagnostic reagents and kits(Does not include license approval items);Biotechnology Extension Services;Biotechnology Development Services;Biotechnology Consulting,communication service;Biotechnology Transfer Services;Biological Products Testing;Import and export(Excluding franchised products);Technology Import and Export;Technology development of stem cell engineering series products;Research and development of stem cell series technical engineering products;Stem Cell Biotechnology Consulting Services;Stem Cell Biotechnology Transfer Services;Stem Cell Biotechnology Services;Licensed medical device business;Manufacture of stem cell series technical engineering products;Preparation of cell preparations and related products;Manufacture of stem cell engineering series products;Sales of stem cell engineering series products;Sales of stem cell series technical engineering products;Sales of cell preparations and related products;collection of stem cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage);Collection of immune cells,storage,preparation service(Without umbilical cord blood hematopoietic stem cell collection,storage)

Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it is the 3rd company of its kind ever created, and has a rich tradition of innovation and commercialization. Through our efforts to identify and create breakthrough scientific research at Hebrew University, we aspire to advance commercial solutions to the most pressing global challenges facing humanity. (Contact Tamir Huberman) Some of our well-known spin-off companies include Mobileye, Orcam, Collplant, Qlight, and Briefcam. Yissum’s business partners span the globe and include companies such as Novartis, Johnson & Johnson, Merck, Intel, Google, Boston Scientific, ICL and many more. Since its inception, Yissum has registered 10,000+ patents covering 2,800+ inventions; licensed 900 technologies and produced 130+ spin-off companies.

LanzaTech New Zealand Ltd., part of LanzaTech Global, Inc., is a company headquartered in Auckland, New Zealand, that develops software for producing ethanol fuel.

American Sterilizer Co., a subsidiary of STERIS Plc (Ireland), is a company headquartered in Pittsburgh, PA, that manufactures sterilization equipment.

Guangzhou Huajin Pharmaceutical Technology Co., Ltd., established on 2016-07-25, The scope of business includes new technologies for drug quality control,New equipment manufacturing;drug development(human stem cells,Except for genetic diagnosis and treatment technology);A New Technology for the Analysis of Active Substances in Natural Medicines,new extraction process,New equipment development and manufacturing;Medical Research and Experimental Development(human stem cells,Except for genetic diagnosis and treatment technology);Pharmaceutical Research Services;Biotechnology Extension Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Development Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Consulting,communication service(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Biotechnology Transfer Services(Rare and unique precious varieties in my country,Wild animals native to my country protected by the state,Except for the development of plant resources);Life Engineering Project Development;Health Sciences Program Research,to develop;Health Sciences Program Research Transfer;Technology Promotion of Research Results of Health Science Projects;Import and export(Except for commodities involving special management regulations on foreign investment access and licensing approval);Technology Import and Export;Commodity wholesale trade(Except for commodities involving special management regulations on foreign investment access and licensing approval);Commodity retail trade(Except for commodities involving special management regulations on foreign investment access and licensing approval);Information Technology Consulting Services;Business Management Consulting Services;Investment Advisory Services;Marketing Planning Service;Natural science research and experimental development;Engineering and Technology Basic Science Research Services;Science and Technology Information Consulting Services;Human Science Research,to develop;